Pertussis toxin enhanced IgG1 and IgE responses to primary tetanus immunization are mediated by interleukin-4 and persist during secondary responses to tetanus alone

Vaccine

Volumn 14, Issue 4, 1996, Pages 290-297

  Samore, Matthew H ^a,b,c   Siber, George R ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

anti tetanus; immune responses; interleukin 4; pertussis toxin; toxoid antibodies

Indexed keywords

IMMUNOGLOBULIN E; IMMUNOGLOBULIN G1; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 4; MONOCLONAL ANTIBODY; PERTUSSIS TOXIN; TETANUS ANTIBODY; TETANUS TOXOID;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNIZATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029868101     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00201-B     Document Type: Article

References (46)

1. Pittman, M. The concept of pertussis as a toxin-mediated disease. Ped. Infect. Dis. 1984, 3, 467-486
2. Tamura, M., Yogimori, K., Murai, S. et al. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 1982, 21, 5516-5522
3. Munoz, J.J. Action of Pertussigen (Pertussis Toxin) on the Host Immune System in Pathogenesis and Immunity in Pertussis (Eds Wardlaw, A.C. and Parton, R.). Wiley and Sons, 1988, pp. 173-192
4. Morse, S.I. and Morse, J.H. Isolation and properties of the leukocytosis and lymphocytosis-promoting factors of Bordetella pertussis. J. Exp. Med. 143, 1976 1483-1502
5. Morse, S.I. and Barron, B.A. Studies on the leukocytosis and lymphocytosis induced by Bordetella pertussis-III. The distribution of transfused lymphocytes in pertussis-treated and normal mice. J. Exp. Med. 1970, 132, 663-672
6. Spangrude, G.J., Sacchi, F., Hill, H.R., Van Epps, D.E. and Daynes, R.A. Inhibition of lymphocyte and neutrophil chemotaxis by pertussis toxin. J. Immunol. 135, 1985 4135-4143
7. Meade, B.D., Kind, P.D., Ewell, J.B., McGrath, P.P. and Manclard, C.R. In vitro inhibition of murine macrophage migration by Bordetella pertussis lymphocytosis-promoting factor. Infect. Immun. 1984, 45, 718-725
8. Samore, M.H. and Siber, G.R. Effect of pertussis toxin on susceptibility of infant rats to Haemophilus Influenzae type b. J. Infect. Dis. 1992
9. Sewell, W.A., Munoz, J.J. and Vadas, M.A. Enhancement of the intensity, persistence, and passive transfer of delayed-type hypersensitivity lesions by pertussigen in mice. J. Exp. Med. 1983, 157, 2087-2096
10. Munoz, J.J., Arai, H., Bergman, R.K. and Sadowski, P.L. Biological activities of crystalline pertussigen from bordetella pertussis. Infect. Immun. 1981, 33, 820-826
11. Andersen, V., Hertz, J.B., Sorennsen, S.F. et al. In vitro stimulation of human lymphocytes by Bordetella pertussis. Acta Path. Microbiol. Scand. 1977, 85 Sect C, 65-72
12. Kashiwa, H., Hyodo, S., Kishi, T. et al. The mitogenic effect of the lymphocytosis promoting factor from Bordetella pertussis on human T and non-T. cells. Clin. Exp. Immunol. 1984, 58, 436-443
13. MacIntyre, E.A., Tatham, P.E.R., Abdul-Gaffar, R. and Linch, D.C. The effects of pertussis toxin on human T lymphocytes Immunology. 1988, 64, 427-432
14. Kong, A.S. and Morse, S.I. The in vitro effects of Bordetella pertussis lymphocytosis-promoting factor on murine lymphocytes. J. Exp. Med. 1977, 145, 151-162
15. Tamura, M., Nogimori, K., Yajima, M., Ase, K. and Ui, M. A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells. J. Biol. Chem. 1983, 258, 6756-6761
16. Nencioni, L., Pizza, M., Volpini, G., De Magistris, M.T., Giovannoni, F. and Rappuoli, R. Properties of the B oligomer of pertussis toxin. Infect. Immun. 1991, 59, 4732-4734
17. Black, W.J., Munoz, J.J., Peacock, M.G. et al. ADP-ribosyltransferase activity of pertussis toxin and immunomodullation by Bordetella pertussis. Science 1988, 240, 656-659
18. O'Hara, J. and Paul, W.E. Production of a monoclonal antibody to and molecular characterization of B-cell stimulator factor-1. Nature 1983, 315, 333-336
19. Furth, M.E., Davis, L.J., Fleurdelys, B. and Scolnick, E.M. Monoclonal antibodies to the p21 products of the transforming gene of harvey murine sarcoma virus and of the cellular ras gene family. J. Virol. 1982, 43, 294-304
20. Baniyash, M. and Eshhar, Z. Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE. Eur. J. Immunol. 1984, 14, 799-807
21. Zollinger, W.D. and Boslego, J.W. A general approach to standardization of the solid-phase radioimmunoassay for quantitation of class specific antibodies. J. Immunol. Meth. 1981, 46, 129-140
22. Finkelman, F.D., Holmes, J., Katona, I.M. et al. Lymphokine control of in vivo immunoglobulin isotype selection. A. Rev. Immunol. 1990, 8, 303-333
23. Mosmann, T.R., Cherwinski, H., Bond, M.W., Giedlin, M.H. and Coffman, R.L. Two types of murine helper T cell clones 1. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol. 1986, 136, 2348-2357
24. Mosmann, T.R. and Coffman, R.L. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. A. Rev. Immunol. 1989, 7, 145-173
25. Finkelman, F.D., Katona, I.M., Urban, J.F. Jr, Smapper, C.M., O'Hara, J. and Paul, W.E. Suppression of in vivo polyclonal IgE responses by monoclonal antibody to the lymphokine B-cell stimulatory factor 1. Proc. Natl Acad. Sci. USA 1986, 83, 9675-9678
26. King, C.L. and Low, C.C., Nutman, TB. IgE production in human helminth infection. Reciprocal interrelationship between IL-4 and IGN-gamma. J. Immunol. 1993, 150, 1873-1880
27. Geha, R.S. Regulation of IgE synthesis in humans. J. Allergy Clin. Immunol. 1992, 90, 143-150
28. Kimata, H., Yoshida, A., Ishioka, C., Lindley, I. and Mikawa, H. Interleukin 8 (IL-8) selectively inhibits immunoglobulin E production induced by IL-4 in human B cells. J. Exp. Med. 1992, 176, 1227-1231
29. Finkelman, F.D., Katona, I.M., Urban, J.F. et al. IL-4 is required to generate and sustain in vivo IgE respones. J. Immunol. 1988, 141, 2335-2341
30. Vercelli, D., Jabara, H.H., Arai, K. and Geha, R.S. Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class Il antigens. J. Exp. Med. 1989, 169, 1294-1307
31. Mu, H.H. and Sewell, W.A. Enhancement of interleukin-4 production by pertussis toxin. Infect Immun. 1993, 61, 2834-2840
32. Gross, A., Ben-Sasson, S.Z. and Paul, W.E. Anti-IL-4 diminishes in vivo priming for antigen-specific IL-4 production by T cells. J. Immunol. 1993, 150, 2112-2120
33. Snapper, C.M., Finkelman, F.D. and Paul, W.E. Differential regulation of IgG1 and IgE synthesis by interleukin-4, J. Exp. Med. 1988, 167, 183-196
34. Kuhn, R., Rajewsky, K. and Muller, W. Generation and analysis of interleukin-4 deficient mice. Science 1991, 254, 707-710
35. Sewell, W.A., DeMoerloose, P.A., Hamilton, J.A., Schrader, J.W., Mackay, I.R. and Vadas, M.A. Potentiation of delayed-type hypersensitivity by pertussigen or cyclophosphamide with release of different lymphokines. Immunology 1987, 61, 483-488
36. Mu, H.H., Penny, R. and Sewell, W.A. Interleukin-5 is necessary for eosinophilia induced by cyclophosphamide in immunized mice. Immunology 1993, 79, 452-458
37. Torre, D., Pugliese, A., Speranza, F. et al. Interferon-γ levels in serum and bronchoalveolar lavage fluid of mice infected with Bordetella pertussis. J. Infect. Dis. 1993, 167, 762-765
38. Torre, D., Issi, M., Giovanni, C., Fiori, G.P. and Sampietro, C. Total serum IgE levels in children with pertussis. Am. J. Dis. Child 1990, 144, 290-291
39. Munoz, J.J. and Bergman, R.K. Bordetella pertussis: Immunological and Other Biological Activities. Marcel Dekker, Inc., New York, 1977
40. Matuhasi, T. and Hakuo, I. Elevation of levels of IgE antibody to tetanus toxin in individuals vaccinated with diphtheria-pertussis-tetanus vaccine. J. Infect. Dis. 1982, 146, 290
41. Howson, C.P. and Fineberg, H.V. Adverse events following pertussis and rubella vaccines. Summary of a report of the Institute of Medicine. J. Am. Med. Assoc. 1992, 267, 392-396
42. Iwasa, S., Ishida, S., Asakawa, S. and Akama, K. A curious histamine-sensitizing activity shown by the newly developed Japanese acellular pertussis vaccine. Dev. Biol. Stand. 1985, 61, 453-460
43. Quentin-Milet, M.J., Arminjon, F., Danve, B., Cadoz, M. and Armand, J. Acellular pertussis vaccines: evaluation of reversion in a nude mouse model. J. Biol. Stand. 1988, 16, 99-108
44. Hedenskop, S., Bjorksten, B., Blennow, M., Granstrom, G. and Granstrom, M. Immunoglobulin E response to pertussis toxin in whooping cough and after immunization with a whole-cell and an acellular pertussis vaccine. Int. Arch. Allergy Appl. Immunol. 1989, 89, 156-161
45. Pizza, M., Covacci, A., Bartoloni, A. et al. Mutants of pertussis toxin suitable for vaccine development. Science 1989, 246, 497-500
46. Siber, G., Wkinberry, L., Todd, C., Samore, M., Sentissi, A. and Cohen, N. Saftey and immunogenicity in adults of pertussis toxoid inactivated with tetranitromethane. Abstracts of the international Workshop on Bordetella pertussis, Rocky Mountain Laboratories, 18-20 August, 1988